Table 1.
Characteristic | No. of patients (%) |
---|---|
Age (years) | |
Median (Range) | 56 (34–81) |
≤ 56 | 61 (50.4) |
> 56 | 60 (49.6) |
Gender | |
Male | 116 (95.9) |
Female | 5 (4.1) |
Body mass index (kg/m2) | |
Median (Range) | 21.3 (15.5–30.0) |
≤ 21.3 | 61 (50.4) |
> 21.3 | 60 (49.6) |
Body surface area (m2) | |
Median (Range) | 1.65 (1.3–2.1) |
≤ 1.65 | 63 (52.1) |
> 1.65 | 58 (47.9) |
Eastern Cooperative Oncology Group performance status | |
0 | 11 (9.1) |
1 | 95 (78.5) |
2 | 14 (11.6) |
3 | 1 (0.8) |
Stage | |
I | 2 (1.7) |
II | 8 (6.6) |
III | 111 (91.7) |
Tumor location | |
U | 51 (42.1) |
M | 30 (24.8) |
L | 17 (14.0) |
U + M (from U to M) | 9 (7.4) |
U + M + L (from U to L) | 1 (0.8) |
M + L (from M to L) | 13 (10.7) |
Smoking | |
Yes | 109 (90.1) |
No | 12 (9.9) |
Alcohol | |
Yes | 111 (91.7) |
No | 10 (8.3) |
Hypertension | |
Yes | 24 (19.8) |
No | 97 (80.2) |
Diabetes | |
Yes | 15 (12.4) |
No | 106 (87.6) |
Cardiovascular disease | |
Yes | 6 (5.0) |
No | 115 (95.0) |
Heart volume (ml) | |
≤ 592 | 61 (50.4) |
> 592 | 60 (49.6) |
Chemotherapy regimen | |
Fluoropyrimidine-based | 113 (93.4) |
Taxane-based | 4 (3.3) |
Others | 4 (3.3) |
Radiation dose (Gy) | |
Median (range) | 61.2 (50–66.6) |
≤ 61.2 | 68 (56.2) |
> 61.2 | 53 (43.8) |
PTV prescribed to 36 Gy (ml) | |
Median (Range) | 780.4 (97.1–1799.5) |
PTV prescribed to 50 Gy (ml) | |
Median (Range) | 640.0 (26.0–1761.2) |
Abbreviations: L Lower thoracic esophagus, M Middle thoracic esophagus, PTV Planning target volume, U Upper thoracic and cervical esophagus